Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.59 |
| ▸ | XBP1 | P17861 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.59 |
| ▸ | SYK | P43405 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | FOS | P01100 | 1/20 | 0.55 |
| ▸ | JUN | P05412 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498501 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTNR2F2NPSR1MAPK1 | |
| SCHEMBL4715162 | 0.99 | ALDH1A1 (0.61) | ALDH1A1MAPTNR2F2NPSR1MAPK1 | |
| SCHEMBL5266863 | 0.99 | ALDH1A1 (0.61) | ALDH1A1MAPTNR2F2NPSR1MAPK1 | |
| SCHEMBL22860692 | 0.98 | ALDH1A1 (0.60) | ALDH1A1MAPTNR2F2NPSR1MAPK1 | |
| SCHEMBL4405587 | 0.95 | ALDH1A1 (0.63) | ALDH1A1MAPTNR2F2NPSR1MAPK1 | |
| SCHEMBL29508872 | 0.91 | ALDH1A1 (0.58) | ALDH1A1MAPTNR2F2NPSR1MAPK1 | |
| SCHEMBL22860492 | 0.91 | ALDH1A1 (0.58) | ALDH1A1MAPTNR2F2NPSR1MAPK1 | |
| SCHEMBL26930607 | 0.91 | ALDH1A1 (0.58) | ALDH1A1MAPTNR2F2NPSR1MAPK1 | |
| SCHEMBL26930605 | 0.91 | ALDH1A1 (0.58) | ALDH1A1MAPTNR2F2NPSR1MAPK1 | |
| SCHEMBL4157935 | 0.90 | ALDH1A1 (0.57) | ALDH1A1MAPTNR2F2NPSR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12097261-B2 | CDK2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| WO-2024173646-A1 | CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| CN-117715904-A | CDK2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3733184-B1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116529251-A | Substituted fused bicyclic compounds as kinase inhibitors and their use | 上海瑛派药业有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2005042519-A1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE -3-KINASES (PI3K) | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1470124-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | BARVIAN MARK (US) | 2003-08-07 | — | — | US | disclosed |
| WO-2003062236-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | disclosed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-0964864-A2 | PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998033798-A2 | PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION | WARNER LAMBERT COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | ALDH1A1 999/4885MAPT 4708/4885NR2F2 882/4885 |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | CDK4, CDKL1, CCNT1 | ALDH1A1 1162/4885MAPT 2259/4885NR2F2 718/4885 |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | CDK4, CDK2, CDK1 | ALDH1A1 1299/4885MAPT 3765/4885NR2F2 1637/4885 |
| US-12097261-B2 | CDK2 degraders and uses thereof | CDK2, CDK20, CDK1 | ALDH1A1 3701/4885MAPT 2735/4885NR2F2 2499/4885 |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | ALDH1A1 3701/4885MAPT 2735/4885NR2F2 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.